GlobeNewswire Inc | Mar 8, 2021 07:00AM EST

March 08, 2021

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the Company or Fate Therapeutics)(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the following upcoming investor conferences:

-- Barclays Global Healthcare Conference on Thursday, March 11, 2021 from 11:30-11:55AM ET -- Oppenheimer Virtual 31st Annual Healthcare Conference on Wednesday, March 17, 2021 from 1:10-1:40PM ET

A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website atwww.fatetherapeutics.com. The archived webcast will be available on the Company's website shortly after the event.

AboutFate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com